Briquilimab (JSP-191) is a non-toxic, humanized monoclonal antibody targeting CD117 (c-Kit) for the depletion of hematopoietic stem cells (HSCs); it is used as a primary conditioning regimen for severe combined immunodeficiency (SCID) to clear host bone marrow niche space, enabling sufficient donor HSC engraftment and immune reconstitution.